Cirrhosis Complications: Variceal Bleeding, Ascites, and Hepatic Encephalopathy Management

Hepatic Encephalopathy: Lactulose and Rifaximin

Hepatic encephalopathy (HE) is graded using the West Haven criteria from covert (grade I) to coma (grade IV). Lactulose remains first-line, titrated to 2-3 soft stools daily, reducing ammonia absorption through colonic acidification and catharsis. Rifaximin 550 mg twice daily added to lactulose reduces HE recurrence by 58% (HR 0.42, 95% CI 0.28-0.64)[3] compared to lactulose alone, as demonstrated in the landmark Bass et al. NEJM 2010 trial. Precipitant identification (infection, GI bleeding, constipation, medications, electrolyte disturbance) and correction is paramount in acute HE episodes. Hepatitis C treatment should be pursued to prevent further liver injury.

Prognostication and Transplant Referral Timing

MELD-3.0 (incorporating sex-adjusted creatinine, bilirubin, INR, sodium, and albumin) is the current allocation model for liver transplant prioritization. MASH-related cirrhosis is now the leading indication for transplant evaluation. Referral to a transplant center should occur at first decompensation event (ascites, variceal bleeding, HE) or MELD score above 15. Median survival after first decompensation is approximately 2 years without transplant[8], underscoring the urgency of early referral.

The Admission Checklist for Decompensated Cirrhosis

When a patient with known or suspected cirrhosis is admitted to the hospital — whether for variceal bleeding, new-onset ascites, confusion, or an unrelated problem — a systematic approach prevents missed interventions. Diagnostic paracentesis should be performed on admission for any patient with ascites, regardless of the primary reason for hospitalization, because SBP is frequently asymptomatic and missed diagnosis is associated with substantially increased mortality. Beta-blocker therapy should be reviewed: if the patient has known varices and is not on a non-selective beta-blocker, this should be addressed before discharge. Hepatic encephalopathy should be actively screened for, even if the patient appears cognitively intact — covert HE is common and underrecognized. And the transplant conversation should be initiated at first decompensation, not deferred until the patient is too sick to undergo evaluation. These steps take minutes and can be protocolized on admission order sets.

Limitations and Gaps in Current Evidence

Cirrhosis complications management is grounded in decades of evidence, but several areas remain uncertain. The optimal beta-blocker dose and target in patients with refractory ascites is debated — concerns about hypotension in patients with already compromised hemodynamics have led some experts to recommend dose reduction or discontinuation in patients with refractory ascites and systolic blood pressure below 90 mmHg, though this remains controversial. The role of TIPS continues to be refined as the indications expand but the risk of hepatic encephalopathy post-TIPS remains a meaningful limitation. And the growing waitlist for liver transplantation means that many patients who would benefit from transplant will not receive one in time, making optimization of non-transplant management strategies all the more important.

References

1. β blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI)
2. β blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI)
3. Rifaximin treatment in hepatic encephalopathy
4. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis
5. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis
6. Portal hypertension and variceal bleeding (D'Amico et al. / Baveno consensus)
7. SBP epidemiology (AASLD/EASL practice guidelines)
8. Natural history of cirrhosis decompensation (D'Amico et al.)